7.99
Precedente Chiudi:
$8.04
Aprire:
$8
Volume 24 ore:
256.33K
Relative Volume:
0.73
Capitalizzazione di mercato:
$183.96M
Reddito:
-
Utile/perdita netta:
$-52.07M
Rapporto P/E:
-38.47
EPS:
-0.2077
Flusso di cassa netto:
$-44.93M
1 W Prestazione:
-3.97%
1M Prestazione:
-3.27%
6M Prestazione:
-20.34%
1 anno Prestazione:
-26.33%
Cybin Inc Stock (CYBN) Company Profile
Nome
Cybin Inc
Settore
Industria
Telefono
908 764 8385
Indirizzo
100 King Street West, Suite 5600, Toronto
Confronta CYBN con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
CYBN
Cybin Inc
|
7.99 | 185.19M | 0 | -52.07M | -44.93M | -0.2077 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Cybin Inc Stock (CYBN) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-03-13 | Iniziato | Guggenheim | Buy |
2021-11-19 | Downgrade | Maxim Group | Buy → Hold |
Cybin Inc Borsa (CYBN) Ultime notizie
What are the technical indicators suggesting about Cybin Inc.Access high-yield investment alerts now - jammulinksnews.com
Should I hold or sell Cybin Inc. stock in 2025Extraordinary performance - jammulinksnews.com
How Cybin Inc. stock performs during market volatilitySolid Return Trade Selections - Metal.it
What analysts say about Cybin Inc. stockSuperior portfolio returns - PrintWeekIndia
Cybin Inc. Stock Analysis and ForecastFree Capital Efficiency Planning - PrintWeekIndia
Is Cybin Inc. a good long term investmentExceptional growth trajectory - PrintWeekIndia
Cybin, Inc: CYB003 Vs. GH001Duration, Durability and Protocol Execution - Smartkarma
What drives Cybin Inc. stock pricePowerful market insights - PrintWeekIndia
Will Cybin Inc. stock benefit from AI tech trendsFree Predictions - jammulinksnews.com
I can have 5% loss. - AInvest
(CYBN) Proactive Strategies - news.stocktradersdaily.com
High-Risk, High-Reward Stocks With Serious Momentum: 5 Stocks to Consider - AInvest
Cybin Inc: CYB003 Phase 3 Program Continues to Progress on Plan - Smartkarma
Weekly Roundup on the Cannabis Sector & Psychedelic Sector - marketexclusive.com
Don't Trip. These Psychedelic Stocks May Have Some Life in Them Yet - US News Money
Wall Street Analysts See an 831.44% Upside in Cybin Inc. (CYBN): Can the Stock Really Move This High? - Yahoo Finance
UK MHRA approves Cybin’s trial of CYB003 for major depressive disorder - Yahoo Finance
Three High-Risk, High-Reward Stocks in AI, Biotech, and Autonomous Vehicles - AInvest
Cybin's EMBRACE Study: A Pivotal Step in Psychedelic-Driven Mental Healthcare Innovation - AInvest
Cybin receives UK MHRA approval to commence EMBRACE study - TipRanks
Rockford Register Star: Local News, Politics & Sports in Rockford, IL - FinancialContent
Cybin Secures UK Approval for Pivotal Depression Study - TipRanks
Cybin receives UK approval for second pivotal depression study By Investing.com - Investing.com India
Cybin receives UK approval for second pivotal depression study - Investing.com
Cybin Receives UK MHRA Approval To Commence EMBRACE, A Multinational Pivotal Study Evaluating CYB003 For The Adjunctive Treatment Of Major Depressive Disorder - TradingView
Cybin Receives UK MHRA Approval to Commence EMBRACE, A Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder - FinancialContent
3 High-Risk, High-Reward Stocks With Explosive Upside - MarketBeat
Three High-Risk, High-Reward Stocks with Explosive Upside: Rezolve AI, Aurora Innovation, and Cybin Inc. - AInvest
Cybin, Inc.CYB003 Vs. Other Aspiring Novel Depression Treatments - Smartkarma
Cybin Inc. Expands Market Strategy with New SEC Filing - The Globe and Mail
Cybin, Inc: Not All Psychedelic Treatments for Depression Are Created Equal - Smartkarma
Cybin Inc Azioni (CYBN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Capitalizzazione:
|
Volume (24 ore):